Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Applying to Johns Hopkins University/Sidney Kimmel Cancer Center · Baltimore, Maryland
Answer a few short questions to share with the research team.